AORT vs EW
AORT: Artivion is a leader in surgical solutions for aortic disease, combining proprietary stent grafts, mechanical heart valves, surgical sealants, and implantable tissue services. EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions.
Side-by-side fundamentals
| Metric | AORT | EW | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $25.14 | $84.37 | |
| Market cap as of 2026-07-23 | $1.2B | $48.6B | |
| P/E as of 2026-07-23 | 103.71 | 44.37 | EW lower |
| PEG as of 2026-07-23 | n/a | 2.00 | |
| Net margin as of 2026-07-23 | +2.5% | +17.4% | EW higher |
| Gross margin as of 2026-07-23 | +64.5% | +77.9% | EW higher |
| Operating margin as of 2026-07-23 | +6.0% | +17.1% | EW higher |
| ROE as of 2026-07-23 | +2.7% | +10.6% | EW higher |
| ROA as of 2026-07-23 | +1.4% | +8.2% | EW higher |
| Debt / equity as of 2026-07-23 | 0.49 | 0.06 | EW lower |
| Revenue growth (YoY) as of 2026-07-23 | +17.6% | +13.8% | AORT higher |
| Revenue CAGR (3y) SEC XBRL | +12.0% | +10.8% | AORT higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.28 | 0.84 | |
| 1-year return as of 2026-07-22 close | -17.3% | +10.4% | EW higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.